ERBB2 and neoplasm: Furthermore, compared to using a HER2 vaccine alone, an intratumoral oHSV-1 booster alters the tumor microenvironment by attracting innate immune cells as well as HER2-specific T cells, leading to an enhanced antitumor effect.